TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • February 28, 2019

SILVER SPRINGS, MD—The FDA approved a label expansion for Imbruvica (ibrutinib) in combination with obinutuzumab to treat adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It is manufactured by Abbvie, North Chicago, IL.